At this year’s Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference, Michael D. Dake, MD, presented a prediction model for treatment outcomes for patients treated with Zilver PTX. The model includes data generated from more than 2,200 patients and provides increased transparency regarding the effects that patients and physicians can expect when using Zilver PTX, Cook Medical’s paclitaxel-coated drug-eluting stent (DES).
Zilver PTX, Cook Medical’s drug-eluting stent
Dr Dake is the senior vice president of health sciences at the University of Arizona, Tucson, and is president-elect of the Society of Interventional Radiology Executive Council. He worked with Cook Research, Inc., to create this prediction model to determine the impact of patient and lesion factors on freedom from target lesion revascularisation (ffTLR) for patients who are candidates for Zilver PTX treatment.
The prediction model was developed by compiling patient factors, lesion characteristics and total lesion revascularisation (TLR) rates from five global studies of the Zilver PTX clinical program. The model was based on data from five different studies and more than 2,200 patients. When creating this model,15 different patient factors were taken into account, including sex, age, lesion length, severity of calcification, diabetes and prior interventions.
‘We are sharing this prediction model and its associated outcomes to continue being transparent with data,’ said Mark Breedlove, vice president of Cook Medical’s vascular division. ‘We hope physicians can use this model to be more informed about Zilver PTX in choosing the best treatment option.’
The prediction model that Dr Dake presented has been published by CardioVascular and Interventional Radiology (CVIR), a peer-reviewed journal, here https://link.springer.com/article/10.1007/s00270-020-02648-6?wt_mc=Internal.Event.1.SEM.ArticleAuthorOnlineFirst.
Dr Michael Dake is a paid consultant for Cook Medical.
This media release is for health care professionals only.